ARID1A and gastric cancer: Our current study demonstrated SMARCA2-attenuated GC exhibited more aggressive course in AJCC stage 3 and non-EBV/MSI diffuse/mixed subtype and ARID1A alteration was associated with more inferior survival in patients with EBV-associated GC.